Skip to main content
LQDALiquidia CorporationHold6.9·$68.50-1.69%

Liquidia (LQDA) Q2 2026 earnings — TrendMatrix coverage

MISS-11.5% vs estimateEPS $0.74 vs $0.84 estVerdict HoldSell

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$0.74
Estimate
$0.84
Surprise
-11.5%
Revenue (period 2026-06-30)
$171.7M
Score at report (before → after)
6.15.8/10

Revenue source: xbrl.

Report record · Q2 2026

How the report landed

Liquidia (LQDA) missed the $0.84 estimate with diluted EPS of $0.74 — a large 11.5% shortfall. TrendMatrix's engine moved from Hold (6.1/10) to Sell at 5.8/10 after the report.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates LQDA Hold at 6.9/10.

2 of the last 4 quarters beat the estimate; this quarter's -11.5% surprise compares with a +12.5% four-quarter average. Next scheduled report: 2026-11-03.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.8 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Product: YUTREPIA
  • Concentration risk — Supplier: single suppliers for YUTREPIA
  • Consecutive earnings misses (2)

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$68.50
Price target
$93.74
Stop
$64.12
Upside to target
+36.8%
Reward-to-risk
3.8:1

The stock trades at 47.7× trailing but 12.3× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

LQDA at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Drug Manufacturers - Specialty & Generic
Market cap
$6.24B
P/E (fwd)
12.3
P/E (ttm)
47.7
52-week range
$21.15$93.61
Off 52-week high
26.8%
RSI (14)
39
Volume vs avg
0.59×
Score today
6.9/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks LQDA Earnings Q2 2026 earnings